NEW YORK (GenomeWeb News) – Althea Technologies said today that Advanced BioScience Laboratories has awarded it a cGMP manufacturing contract worth $911,549 to produce a DNA-based HIV-1 vaccine.
The multi-year contract is under a master agreement with the US National Institutes of Health and funded by the National Institute of Allergy and Infectious Diseases, Althea said.
It will “support Althea's efforts for plasmid DNA process development, vaccine production, purification, and regulatory documentation,” the company said in a statement.
Terms of the deal call for Althea to support a “larger vaccine development program” that is in conjunction with the South African AIDS Vaccine Initiative.